Oruka Therapeutics (ORKA) versus Its Rivals Critical Review

Oruka Therapeutics (NASDAQ:ORKA) is one of 36 publicly-traded companies in the “Diagnostic substances” industry, but how does it compare to its competitors? We will compare Oruka Therapeutics to related companies based on the strength of its analyst recommendations, institutional ownership, earnings, dividends, valuation, risk and profitability.

Analyst Recommendations

This is a summary of current ratings and price targets for Oruka Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	851	800	1339	23	2.18

Oruka Therapeutics currently has a consensus target price of $43.17, suggesting a potential upside of 45.05%. As a group, “Diagnostic substances” companies have a potential upside of 33.53%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Oruka Therapeutics is more favorable than its competitors.

Profitability

This table compares Oruka Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-456.55%	-21.40%	-14.61%

Institutional & Insider Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 47.3% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 12.7% of shares of all “Diagnostic substances” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Oruka Therapeutics and its competitors top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-4.96
Oruka Therapeutics Competitors	$602.64 million	$7.11 million	-35.52

Oruka Therapeutics’ competitors have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Oruka Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ competitors have a beta of 1.20, indicating that their average share price is 20% more volatile than the S&P 500.

Summary

Oruka Therapeutics beats its competitors on 9 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.